Telix Pharmaceuticals (TLX) Notes Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Notes Payables for 3 consecutive years, with $13.1 million the latest figure, recorded in Q4 2025.

• Quarterly Notes Payables fell 2.25% year-over-year to $13.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.1 million (down 2.25% YoY) and the FY2025 annual result came in at $13.1 million, up 11.45% from the prior year.
• Notes Payables declined to $13.1 million in Q4 2025 per TLX's latest filing, from $13.4 million in the prior quarter.
• Over the last five years, Notes Payables for TLX reached as high as $13.4 million in Q4 2024 and fell as low as $680800.6 in Q4 2023.
• A 3-year average of $9.1 million and a median of $13.1 million in 2025 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables surged 1869.92% — and 2025, when it slipped 2.25%.
• Year by year, Notes Payables stood at $680800.6 in 2023, then jumped by 1869.92% to $13.4 million in 2024, then slipped by 2.25% to $13.1 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $13.1 million, $13.4 million, and $680800.6 for Q4 2025, Q4 2024, and Q4 2023 respectively.